An Emerging Nanomedicine Leader

Spago Nanomedical is a Swedish company in clinical development phase with a proprietary platform of polymeric materials to bring more precise treatment and imaging diagnostics of cancer and other severe diseases.

Our development projects, Tumorad^® and SpagoPix have unique properties with potential to significantly improve healthcare for the benefit of large groups of patients. With Tumorad®, preclinical results show that the candidate drug in the program, 177Lu-SN201, accumulates in tumors, delays growth and prolongs survival at clinical useful doses. This opens up for wide use of 177Lu-SN201 for the treatment of various cancers where there are currently no opportunities for clinically effective treatment with radiopharmaceuticals, such as ovarian cancer and triple-negative breast cancer. A phase I/IIa clinical study in patients with advanced cancer is ongoing to evaluate safety, tolerability, biodistribution and initial efficacy of 177Lu-SN20. With SpagoPix, initial clinical results show that the product candidate within the program, pegfosimer manganese (formerly SN132D), provides clinically relevant contrast in breast cancer tumors, in the liver and in the pancreas, while maintaining good safety. Selective contrast enhancement has also been observed in endometriosis lesions in a clinical phase IIa clinical study.